Does deep sedation impact the results of 48 hours catheterless pH testing?

作     者：Vineet Korrapati Jay P Babich Anil Balani James H Grendell, Kavita R Kongara Anil Balani James H Grendell Kavita R Kongara 

作者机构：Department of Gastroenterology and Hepatology Win-throp University Hospital Mineola NY 11501 United States Department of Gastroenterology and HepatologyUMDNJ-RWJ Medical School New Brunswick NJ 08901United States 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2011年第17卷第10期

页      面：1304-1307页

核心收录：

学科分类：1002[医学-临床医学] 100217[医学-麻醉学] 10[医学] 

基　　金：Supported by Winthrop University Hospital 

主　　题：Esophagus Bravo study Propofol pH cap-sule Gastroesophageal reflux disease 

摘      要：AIM： To study a cohort of patients undergoing 48 h Bravo pH testing receiving deep sedation with propofol. METHODS： We retrospectively reviewed the charts of 197 patients （81 male, 116 female） who underwent Bravo esophageal pH monitoring from July 2003 to January 2008. All patients underwent Bravo pH probe placement via esophagogastroduodenoscopy （EGD） and received propofol for sedation. Patients on a proton pump inhibitor （89 patients） were excluded. Acid reflux variables measured included the total, upright, and supine fractions of time at pH 〈 4 and DeMeester score, and were compared between day I and day 2. RESULTS： Of the 108 patients that were included in the study, the most common indication for Bravo pH monitoring was heartburn, with chest pain being the second most common. A signed rank test revealed no statistically significant difference between day I and day 2 reflux episodes. CONCLUSION： Patients who received propofol for sedation for EGD with Bravo pH capsule placement did not experience any significant difference in reflux episodes from day 1 to day 2.